News | Clinical Decision Support | October 23, 2018

Impathiq Heart Pathway Clinical Decision Support Tool Featured in Circulation

Accelerated diagnostic protocol shown to be safe and effective as CDS tool for patients presenting with chest pain

Impathiq Heart Pathway Clinical Decision Support Tool Featured in Circulation

October 23, 2018 — Health informatics company Impathiq announced its Heart Pathway point-of-care clinical decision support tool was recently featured in the American Heart Association journal Circulation. The article, “Safely Identifying Emergency Department Patients with Acute Chest Pain for Early Discharge: The HEART Pathway Accelerated Diagnostic Protocol” appeared Sept. 28 in Circulation.1

This summer, Heart Pathway was successfully installed across the Boston-area Cambridge Health Alliance to streamline chest pain care in its emergency departments, which serve about 100,000 patients a year. The goal is strengthening patient care while reducing the number of low-risk chest pain admissions.  

The Circulation article focused on results from a three-year clinical study of 8,474 adult emergency department patients. The study examined the safety and effectiveness of Impathiq’s health informatics technology as a means of providing point-of-care clinical decision support for patients presenting chest pain. As reported in Circulation, the implementation of Heart Pathway was associated with decreased hospitalizations, increased identification of index visit myocardial infarctions, and a very low death and myocardial infarction rate among low-risk patients.

“The most important finding is that the Heart Pathway identified [more] than 30 percent of patients as low-risk with an adverse event rate among low-risk patients of only 0.4 percent,” said Simon Mahler, M.D., Impathiq chief medical officer and lead author of the Circulation piece. He added, “Our study adds to a growing body of evidence suggesting that current ACC/AHA guidelines recommending stress testing or CT [computed tomography] angiography among low-risk emergency department patients are now obsolete.”

Mahler explained that a key takeaway from this study for physicians is that the Heart Pathway is safe and effective at identifying emergency department patients for early discharge without stress testing or coronary CT angiography. He added that the Heart Pathway identified more than 30 percent of patients as low-risk, with an adverse event rate among low-risk patients of 0.4 percent. Emergency department physicians should use an accelerated diagnostic protocol (ADP), such as the Heart Pathway, to guide their testing and disposition decisions, he said.

Heart Pathway is available on Cerner, Epic and other electronic health record (EHR) platforms and can be easily installed by health systems in a fashion similar to installing an app on a smartphone. Heart Pathway asks healthcare providers a series of objective questions about patient symptoms, risk factors and EKG findings. The tool then produces a risk score and recommendation, documenting results directly into the EHR while providing administrators access to valuable statistics to help standardize care across an entire system.

For more information: www.impathiq.com

Reference

1. Mahler S.A., Lenoir K.M., Wells B.J., et al. Safely Identifying Emergency Department Patients with Acute Chest Pain for Early Discharge: The HEART Pathway Accelerated Diagnostic Protocol. Circulation, Sept. 28, 2018. www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.118.036528

 

Related Content

The BardyDx Carnation Ambulatory Monitor (CAM) is a P-wave centric wearable ambulatory cardiac patch monitoring and arrhythmia detection device. 

The BardyDx Carnation Ambulatory Monitor (CAM) is a P-wave centric wearable ambulatory cardiac patch monitoring and arrhythmia detection device. 

News | Cardiac Diagnostics | July 29, 2021
July 29, 2021 — A recent clinical study from Overlake Medical Center utilizing the Bardy Diagnostics Carnation Ambula
The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device

The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device

News | Cardiac Diagnostics | July 01, 2021
July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc.
Ophthalmic optical coherence tomography (OCT) scan view of the macula in retina with vessels. Detecting heart disease with OCT imaging of the eye.Getty Images

Ophthalmic optical coherence tomography (OCT) scan view of the macula in retina with vessels. Getty Images
 

News | Cardiac Diagnostics | March 08, 2021
March 8, 2021 — In a new study from Shiley Eye Institute at UC San Diego Health, researchers have identified a potent
Alivecor's pocket ECG system allows consumers or cardiologists to record a single lead ECG. AI algorithms can determine if their ECG is normal or abnormal and identify the arrhythmia.

Alivecor's pocket ECG system allows consumers or cardiologists to record a single lead ECG strip on a smartphone. AI algorithms can determine if their ECG is normal or abnormal and identify the arrhythmia. 

News | Cardiac Diagnostics | March 03, 2021
March 3, 2021 — AliveCor recently announced a new collaboration with AstraZeneca to research new disease management s
A study of more than 100 million Americans in 3,123 counties found a correlation between cardiac death and their level of income. Getty Images Health disparities in cardiovascular disease.

A study of more than 100 million Americans in 3,123 counties found a correlation between cardiac death and their level of income. Getty Images

News | Cardiac Diagnostics | February 02, 2021
February 2, 2021 — A new study has found in the U.S.
A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

News | Cardiac Diagnostics | January 06, 2021
January 6, 2021 — Smoking traditional cigarettes in addition to using e-cigarettes results in harmful health effects
The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia.

The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia. 

News | Cardiac Diagnostics | October 06, 2020
October 6, 2020 — A new technology being developed by U.S.-based Mesuron Inc.
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. Amyloidosis Patient Registry  #Amyloidosis

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

News | Cardiac Diagnostics | March 05, 2020
March 5, 2020 — More than 300 patients have joined the Amyloidosis Patient Registry and it is now available to the en